Lymphoblastic Lymphoma In Adults

  • John Sweetenham


Lymphoblastic lymphoma (LBL) accounts for approximately 4% of all adult patients with non-Hodgkin’s lymphoma (NHL). It is recognised as a distinct clinopathological entity in all of the recently described classifications for NHL, including the Revised European-AmeriPcan Lymphoma (REAL) classification. It is a neoplasm of precursor T or B lymphocytes, which is very similar to acute lymphoblastic leukaemia on the basis of morphology and phenotype. The distinction between ALL and LBL is variable between different treatment centres, and usually based on arbitrary clinical grounds, particularly the degree of bone marrow infiltration or leukaemic overspill. Because of its rarity, it has been the subject of relatively few series in the published literature, and several aspects of its management remain unclear. The results of treatment have improved in recent years, particularly with the use of intensive remission induction therapy similar to that used in acute lymphoblastic leukaemia (ALL). With intensive chemoradiotherapy, most recent series have reported remission rates of 60% to 80%, with long term disease free survival reported in 40% to 60% of patients. Therefore, although high remission rates can be achieved with conventional dose combination chemotherapy, the relapse and progression rate is high. The use of dose intensive therapy in first remission, particularly high dose therapy with stem cell transplantation, has been reported in several series, although its role remains unclear. Similarly, the selection of patients who are at high risk of relapse or progression with conventional therapy has not been reported consistently. The optimal management of patients who fail first line therapy also remains a difficult clinical problem.


Overall Survival Clin Oncol Autologous Stem Cell Transplanatation Acute Lymphoblastic Leukaemia Autologous Bone Marrow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    . Drexler H, Thiel E, Ludwig WD. Review of the incidence and clinical relevence of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia 1991; 5: 637PubMedGoogle Scholar
  2. 2.
    . Sixth international workshop on chromosomes in leukemia: London, England, May 11– 18,1987: Selected papers. Cancer Genet Cytogenet 1989; 40: 171CrossRefGoogle Scholar
  3. 3.
    . Weiss L, Bindl J, Picozzi V, et al. Lymphoblastic lymphoma: An immunophenotypic study of 26 cases with comparison to T cell acute lymphoblastic leukemia. Blood 1986; 67: 474PubMedGoogle Scholar
  4. 4.
    Swerdlow S, Habeshaw J, Richards M, et al. T lymphoblastic lymphoma with Leu-7 positive phenotype and unusual clinical course: A multiparameter study. Leuk Res 1985; 9: 167PubMedCrossRefGoogle Scholar
  5. 5.
    . Sheibani K, Winberg C, Burke J. Lymphoblastic lymphoma expressing natural killer cell-associated antigens. A clinicopathologic study of six cases. Cancer 1987; 60: 183PubMedCrossRefGoogle Scholar
  6. 6.
    . Sheibani K, Nathwani B, Winberg C. Antigenically defined subgroups of lymphoblastic lymphoma: Relationship to clinical presentation and biologic behavior. Cancer 1987; 60: 183PubMedCrossRefGoogle Scholar
  7. 7.
    . Coleman CN, Picozzi VJ, Cox RS, et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 1626– 1637Google Scholar
  8. 8.
    . Morel P, Lepage E, Brice P, et al. Prognosis and treatment of lymphoblastic lymphoma in adults: A report on 80 patients. J Clin Oncol 1992; 10: 1078 – 1085Google Scholar
  9. Bernasconi C, Brusamolino E, Lazzarino M, et al. Lymphoblastic lymphoma in adult patients; Clinico-pathological features and response to intensive multi agent chemotherapy analogous to that used in acute lymphoblastic leukemia. Ann Oncol 1990; 1: 141 – 146Google Scholar
  10. 10.
    . Slater DE, Mertelsmann R, Koriner B, et al. Lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 57 – 67PubMedGoogle Scholar
  11. Sweetenham JW, Mead GM, Whitehouse JMA. Adult lymphoblastic lymphoma: High incidence of central nervous system relapse in patients treated with the Stanford University protocol. Ann Oncol 1992; 3: 839 –841Google Scholar
  12. 12.
    . Wollner N, Burchenal JH, Lieberman PH, et al. Non-Hodgkin’s lymphoma in children. A progress report on the original patients treated with the LSA2L2 protocol. Cancer 1979; 44: 1990 – 1999Google Scholar
  13. The International Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987 – 994Google Scholar
  14. 14.
    Santini G, Coser P, Chisesi T, et al. Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Ann Oncol 1991; 2 (suppl 2): 181 – 185PubMedGoogle Scholar
  15. 14.
    Milpied N, Ifrah N, Kuentz M, et al. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 1989; 73: 82 – 87PubMedCrossRefGoogle Scholar
  16. 16.
    Verdonck LF, Dekker AW, de Gast GC, et al. Autologous bone marrow transplantation for adult poor risk lymphoblastic lymphoma in first remission. J Clin Oncol 1992; 10: 644 – 646PubMedGoogle Scholar
  17. Jackson GH, Lennard AL, Taylor PRA, et al. Autologous bone marrow transplantation in poor risk high grade non-Hodgkin’s lymphoma in first complete remission. Br J Cancer 1994; 70: 501 – 505Google Scholar
  18. 18.
    . Sweetenham JW, Liberti G, Pearce R, et al. High dose therapy and autologous bone marrow transplanta¬tion for adult patients with lymphoblastic lymphoma: Results of the European Group for Bone Marrow Transplantation. J Clin Oncol 1994; 12: 1358 – 1365Google Scholar
  19. 19.
    Jost LM, Jacky E, Dommann-Scherrer C, et al. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt’s lymphomas in adult patients. Ann Oncol 1995; 6: 445 – 451PubMedGoogle Scholar
  20. 20.
    . Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group registry data. J Clin Oncol 1992; 11: 1690 – 1695Google Scholar
  21. 21.
    Shpall EJ, Jones RB, Bearman SI, et al. Transplantation of enriched CD34-positive autologous bone marrow into breast cancer patients following high dose chemotherapy: influence of CD34-positive pripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28 – 31PubMedGoogle Scholar
  22. 22.
    Haas R, Witt B, Goldschmidt H, et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754 – 3761Google Scholar
  23. 23.
    Sharp JC, Kessinger A, Mann S, et al. Detection and clinical significance of minimal tumor cell contamination of peripheral blood stem cell harvests. Int J Cell Cloning 1992; 10 (suppl 2): 92 – 96CrossRefGoogle Scholar
  24. 24.
    Gribben JG, Neuberg D, Barber M, et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83: 3800– 3807PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1996

Authors and Affiliations

  • John Sweetenham
    • 1
  1. 1.CRC Wessex Medical Oncology UnitUniversity of Southampton Southampton General HospitalSouthamptonUK

Personalised recommendations